What is in the pipeline for Gram-negative pathogens?

References

• Green M, Martin JM, Barbadora KA, Beall B, Wald ER. Reemergence of macrolide resistance in pharyngeal isolates of group A streptococci in southwestern Pennsylvania. Antimicrob. Agents Chemother.48(2), 473–476 (2004).
   PubMed Web of Science ®Google Scholar
• Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld ME, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infections Diseases Society of America. Clin. Infect. Dis.42, 657–668 (2006).
   PubMed Web of Science ®Google Scholar
• Quale J, Bratu S, Landman D, Heddurshetti R. Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii epidemic in New York City. Clin. Infect. Dis.37, 214–220 (2003).
   PubMed Web of Science ®Google Scholar
• Gales AC, Jones RN, Forward KR, Liñares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997–1999). Clin. Infect. Dis.32, S104–S113 (2001).
   PubMed Web of Science ®Google Scholar
• Carey RB, Banerjee S, Srinivasan A. Multidrug-resistant Acinetobacter infections 1995–2004. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract K-1495).
   Google Scholar
• Falagas ME, Kasiakou SK. Colistin: the revival of polymixins for the management of multidrug-resistant Gram-negative bacterial infections. Clin. Infect. Dis.40, 1333–1341 (2005).
   PubMed Web of Science ®Google Scholar
• Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int. J. Antimicrob. Agents25(1), 11–25 (2005).
   PubMed Web of Science ®Google Scholar
• Macone A, Donatelli J, Dumont T, Levy SB, Tanaka SK. In-vitro activity of PTK0796 against Gram-positive and Gram-negative organisms. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 14–17 September (2003) (Abstract F-754).
   Google Scholar
• Tessier PR, Fan HW, Tanaka SK, Nicolau DP. Pharmacokinetic/pharmacodynamic profile of MK-2764/PTK0796 against S. pneumoniae in a murine pneumonia model. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract F1-1973).
   Google Scholar
• Andes DR, Craig W, Odinecs A. In vivo pharmacodynamics of MK-2764/PTK-0796 against various Gram-positive and Gram-negative bacteria in the thighs of neutropenic and normal mice. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract F1-1974).
   Google Scholar
• McKenney D, Quinn JM, Jackson CL et al. Evaluation of PTK0796 in experimental models of infections caused by Gram-positive and Gram-negative pathogens. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 14–17 September (2003) (Abstract F-757).
   Google Scholar
• Traczewski MM, Brown SD. PTK0796: in vitro potency and spectrum of activity compared to ten other antimicrobial compounds. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 14–17 September (2003) (Abstract F-753).
   Google Scholar
• Zhanel GG, Decorby M, Laing N et al. Activity of tigecycline against 3807 pathogens obtained from Canadian intensive care units; results of the Canadian national intensive care (CAN-ICU) study. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract E-743).
   Google Scholar
• Scheetz MH, Qi C, Warren JR et al. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.Antimicrob. Agents Chemother.51(5), 1621–1626 (2007).
   PubMed Web of Science ®Google Scholar
• Perez F, Hujer AM, Huger KM, Decker BK, Rather PN, Bonomo RA. The global challenge of multidrug resistant (MDR) Acinetobacter baumannii.Antimicrob. Agents Chemother. (2007) (In press).
   Google Scholar
• Munoz-Price LS, Zembower T, Schreckenberger PC et al. Tigecycline (TG) vs. colistin (Co) for the treatment of multidrug-resistant (MDR) Acinetobacter baumannii (Ab) blood stream infection (BSI). Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract K-389).
   Google Scholar
• Barrios J, Blanco R, Calvo F et al. Activity of tigecycline against Acinetobacter baumannii. Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract E-285).
   Google Scholar
• Bakshi A, Surya H, Verma D et al. Comparative in vitro susceptibility of tigecycline and polymyxin B for resistant Klebsiella and Acinetobacter isolates. Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract E-917).
   Google Scholar
• Ellis-Grosse EJ. Glycylcyclines: A new class of antibiotics for the changing pathogen landscape. Presented at: SMI Conference: Super Bugs and Super Drugs. London, UK, 24–25 April (2006).
   Google Scholar
• Schafer JJ, Goff DA, Stevenson KB, Mangino JE. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multi-drug resistant Acinetobacter baumannii.Pharmacotherapy27(7), 980–987 (2006).
   Google Scholar
• Stein G, Craig W. Tigecycline: a critical analysis. Clin. Infect. Dis.43, 518–524 (2006).
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Tigecycline (TGC) concentrations (Cp) in lung tissue, cerebrospinal fluid (CSF), and bile of human subjects. Proceedings of the 45rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 16–19 December (2005) (Abstract A-18).
   Google Scholar
• Dukart G, Dartois N, Cooper CA, Gandjini H, Ellis-Grosse EJ. Integrated results of 2 Phase 3 studies comparing tigecycline (TGC) with levofloxacin (LEV) in patients (Pts) with community-acquired pneumonia (CAP). Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract L-1450).
   Google Scholar
• Maroko R, Cooper A, Dukart G, Dartois N, Gandjini H. Results of Phase 3 study comparing a tigecycline (TGC) regimen with an imipenem/cilastatin (IMI) regimen in treatment of patients (Pts) with hospital-acquired pneumonia (HAP). Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract L-730).
   Google Scholar
• Page MGP, Desarbre E, Geier C, Hofer B. Activity of BAL30376 against Gram-negative bacteria. Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract F1-312).
   Google Scholar
• Bowker KE, Noel AR, MacGowan AP. In vitro potency of BAL30376 against Gram-negative bacilli (GNB). Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract F1-313).
   Google Scholar
• Schmitt-Hoffmann A, Gebhardt K, Gaucher B, Desarbre E, Page M. Efficacy of BAL30376 in a murine model of Gram-negative sepsis. Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract F1-315).
   Google Scholar
• Ishii Y, Sugihara S, Tateda K, Yamaguchi K. In vitro synergistic effects of combinations of CP3242, as a novel metallo-β-lactamase inhibitor, and carbapenems against carbapenemase producing organisms. Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract F1-331).
   Google Scholar
• Osaki Y, Morinaka A, Mikuniya et al. CP3242, a novel metallo-β-lactamase inhibitor: in vitro and in vivo efficacy against clinically isolated metallo-β-lactamase-producing P. aeruginosa. Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract F1-332).
   Google Scholar
• Muto Y, Matsumoto K, Morinaka A et al. CP3242, a novel metallo-β-lactamase inhibitor: pharmacokinetics and in vivo pharmacodynamic activities against metallo-β-lactamase-producing P. aeruginosa in a murine thigh infection model. Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract F1-333).
   Google Scholar
• Brown NP, Jones ME, Draghi DC, Cohen MA, Thornsberry C, Sahm DF. Baseline surveillance profile of doripenem (DOR) against key Gram-negative pathogens encountered in the United States. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract E-221).
   Google Scholar
• Fritsche TR, Sader HS, Jones RN. Geographic variations in the activity of doripenem and other broad spectrum agents: results from an international surveillance program (2003–2005). Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract C2-1836).
   Google Scholar
• Fritsche TR, Sader HS, Strabala P, Jones RN. Antimicrobial activities of doripenem and other carbapenems tested against Pseudomonas aeruginosa, other non-fermentative bacilli and Aeromonas spp. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract E-222).
   Google Scholar
• Chen Y, Garber E, Zhao Q et al. In vitro activity of doripenem (S-4661) against multidrug-resistant Gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother.49(6), 2510–2511 (2005).
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa: in vitro activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob. Agents Chemother.48(8), 3086–3092 (2004).
   PubMed Web of Science ®Google Scholar
• Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa.Antimicrob. Agents Chemother.44(12), 3322–3327 (2000).
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Umeh O, Jiang J, Kaniga K, Friedland I. Doripenem vs. meropenem with an option for oral step-down therapy in the treatment of complicated intra-abdominal infections. Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract L-487).
   Google Scholar
• Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of doripenem vs. imipenem for ventilator-associated pneumonia. Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract L-486).
   Google Scholar
• Réa-Neto Á, Niederman M, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous doripenem vs. piperacillin/tazobactam in nosocomial pneumonia. Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract L-731).
   Google Scholar
• Sesoko S, Morita K, Tajima N, Nakashima M. Safety, tolerability and pharmacokinetics of CS-023 (RO4908463), a new parenteral carbapenem in healthy male Japanese volunteers. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract A-1941).
   Google Scholar
• Jones ME, Cohen MA, Brown NP, Dannemann B, Sahm DF. Bactericidal activity of RO4908463 (CS-023) against β-lactam susceptible and resistant target species. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract E-227).
   Google Scholar
• Jones ME, Cohen MA, Brown NP, Dannemann B, Sahm DF. Baseline profile of RO4908463 (CS-023) against recent isolates of target Gram-negative pathogens exhibiting β-lactam resistance phenotypes. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract C2-1835).
   Google Scholar
• Jones ME, Cohen MA, Brown NP, Dannemann B, Sahm DF. Baseline profile of CS-023 (RO4908463) against recent isolates of target Gram-positive pathogens exhibiting key resistance phenotypes. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract E-228).
   Google Scholar
• Jones ME, Cohen MA, Brown NP, Dannemann B, Sahm DF. RO4908463 (CS-023) demonstrates a low potential for in vitro selection of resistance in S. aureus (SA), E. coli (EC), and P. aeruginosa (PA). Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract C1-35).
   Google Scholar
• Koga T, Abe T, Inoue H et al. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem. Antimicrob. Agents Chemother.49(8), 3239–3250 (2005).
   PubMed Web of Science ®Google Scholar
• Rennecke J, Hirota T, Shibayama T et al. Safety, tolerability, and pharmacokinetics (PK) of CS-023, a new parenteral carbapenem, in healthy male volunteers. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA, 27–30 September (2002) (Abstract F-327).
   Google Scholar
• Shibayama T, Matsushita Y, Hirota T, Ikeda T, Kuwahara S. Pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem, in healthy male Caucasian volunteers. Antimicrob. Agents Chemother.50(12), 4186–4188 (2006).
   PubMed Web of Science ®Google Scholar
• Turner S. Antibacterials, R&D update. Daiichi Sankyo confirms update of anti-infective R&D pipeline. Anti Infect. Drug News135, 3 (2007).
   Google Scholar
• Bush K, Heep M, Macielag MJ, Noel GJ. Anti-MRSA β-lactams in development, with a focus on ceftobiprole: the first anti-MRSA β-lactam to demonstrate clinical efficacy. Expert Opin. Invest. Drugs16(4), 419–429 (2007).
   PubMed Web of Science ®Google Scholar
• Aranza MK, Pillar CM, Draghi DC, Jones ME, Thornsberry C, Sahm DF. Profile of ceftobiprole activity against S. ureus, S. pneumoniae, Enterobacteriaceae, P. aeruginosa, and Acinetobacter spp: results of the 2005–2006 surveillance program. Presented at: European Conference on Clinical Microbiology and Infectious Diseases. Munich, Germany, 31–3 April (2007) (Abstract 2024).
   Google Scholar
• Fritsche TR, Sader HS, Jones RN. in vitro activity of ceftobiprole tested against a recent collection of North American Pseudomonas aeruginosa. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract E-115).
   Google Scholar
• Fritsche TR, Sader HS, Strabala PA, Jones RN. Activity of ceftobiprole tested against staphylococcal and streptococcal isolates recovered from patients in European medical centres (2005–2006). Presented at: European Conference on Clinical Microbiology and Infectious Diseases. Munich, Germany, 31–3 April (2007) (Abstract 781).
   Google Scholar
• Amsler KM, Bajaksouzian S, Windau A, Jacobs MR, Bush K. Ceftobiprole activity against pathogens from two complicated skin and skin structure infection (cSSSI) clinical trials. Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract E-282).
   Google Scholar
• Brown NP, Jones ME, Draghi DC et al. Baseline surveillance profiles of ceftobiprole (BPR) activity against Enterobacteriaceae and P. aeruginosa (PA). Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract E-112).
   Google Scholar
• Hujer AM, Bethel CR, Shapiro S, Patterson DL, Page MGP, Bonomo RA. in vitro activity of BAL9141, a broad spectrum pyrrolidinone cephalosporin, against Klebsiella pneumoniae isolates possessing extended spectrum β-lactamases (ESBLs). Proceedings of the43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA 14–17 September (2003) (Abstract F-542).
   Google Scholar
• Noel GJ, Strauss RS, Pypstra R; 00154 Study Group. Successful treatment of complicated skin infections (cSSSI) due to staphylococci, including methicillin-resistant Staphylococcus aureus (MRSA) with ceftobiprole. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract L-1212).
   Google Scholar
• Pillar CM, Aranza, MK, Shah D, Sahm DF. A profile of ceftobiprole (BPR) activity against recent U.S. isolates of Enterobacteriaceae (EN) and Pseudomonas aeruginosa (PA) from inpatients and ICU patients. Proceedings of the47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract E-272).
   Google Scholar
• Strauss RS, Partha B, Noel GJ. Successful treatment of complicated skin and skin structure infections (cSSSI) due to a broad spectrum of bacteria with ceftobiprole (BPR). Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract L-1145).
   Google Scholar
• Takeda S, Nakai T, Wakai Y, Ikeda F, Hatano K. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa.Antimicrob. Agents Chemother.51(3), 826–830 (2007).
   PubMed Web of Science ®Google Scholar
• Lomovskaya O, Bostian KA. Practical applications and feasibility of efflux pump inhibitors in the clinic – a vision for applied use. Biochem. Pharmacol.71(7), 910–918 (2006).
   PubMed Web of Science ®Google Scholar
• Mahamoud A, Chevalier J, Alibert-Franco S, Kern WV, Pagès JM. Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy. J. Antimicrob. Ther.59(6), 1223–1229 (2007).
   PubMed Web of Science ®Google Scholar
• Gentile A, Saechao B, Myers M, Lomovskaya O, Griffith D. Pharmacodynamics of levofloxacin (LVX) with or without the broad spectrum efflux pump inhibitor (EPI), MC-02,595 (595), in a neutropenic mouse thigh infection model due to strains of P.aeruginosa (PA) overexpressing efflux pumps. Proceedings of the46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, 27–30 September (2006) (Abstract A-15).
   Google Scholar
• King P, Gentile A, Saechao B, Myers M, Lomovskaya O. Impact of efflux pumps and target mutations on activity of multiple fluoroquinolones (FQs) against Pseudomonas aeruginosa (PA). Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract C1-44).
   Google Scholar
• Jenssen H, Hamill P, Hancock REW. Peptide antimicrobial agents. Clin. Microbiol. Rev.19, 491–511 (2006).
   PubMed Web of Science ®Google Scholar
• Rodríguez-Hernández MJ, Saugar J, Docobo-Pérez F et al. Studies on the antimicrobial activity of cecropin A–melittin hybrid peptides in colistin-resistant clinical isolates of Acinetobacter baumannii.J. Antimicrob. Chemother.58, 95–100 (2006).
   PubMed Web of Science ®Google Scholar
• Sturgess MA, Appelbaum PC, Difranco JM, Koeth LM. Synergistic in vitro activity of DnaK inhibitors and levofloxacin against Gram-negative organisms. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract F2-1167).
   Google Scholar
• Savage PB, Orsak T, Burns JL. A cationic steroid active against highly tobramycin-resistant Pseudomonas aeruginosa. Presented at: National Foundation for Infectious Diseases Conference. Bethesda, MD, USA, 27–29 June (2005) (Abstract P12).
   Google Scholar
• Savage PB, Genberg C, Jones RN et al. Activity of a novel cationic steroid antimicrobial (CSA-13) targeting aerobic and facultative Gram-negative bacilli, Gram-positive anaerobes and select agent surrogate strains. Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 16–19 December (2005) (Abstract F-1231).
   Google Scholar
• Savage PB, Lai X, Feng Y, Genberg C. Anti-biofilm activities of ceragenin CSA-13 and vancomycin against Gram-positive and -negative bacteria. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract F1-1865).
   Google Scholar
• Bucki R, Sostarecz AG, Savage P, Janmey PA. Activity of ceragenin CSA-13 in the polyelectrolyte environment of cystic fibrosis airway fluid compared to cathelicidin LL-37. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract F1-1870).
   Google Scholar
• Rhomberg PR, Streit JM, Jones RN, Fritsche TR. Activity of omiganan against contemporary (2005–2006) Gram-positive pathogens responsible for catheter colonization and catheter-related bloodstream infections. Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract E-2092).
   Google Scholar
• Escaich S, Moreau F, Floquet S et al. Discovery of new Gram-negative antivirulence drugs 2: characterization of novel E. coli RfaE inhibitors. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract F2-496).
   Google Scholar
• Denis A, Moreau F, Genevard J et al. Discovery of new Gram-negative antivirulence drugs 1: structure and properties of novel E. coli WaaC inhibitors. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract F2-1169).
   Google Scholar
• Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in the treatment of complicated skin and skin structure infections. Antimicrob. Agents Chemother.51(10), 3612–3616 (2007).
   PubMed Web of Science ®Google Scholar
• Sader HS, Fritsche TR, Kaniga K, Ge Y, Jones RN. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin tested against a worldwide collection of clinical strains. Antimicrob. Agents Chemother.49(8), 3501–3512 (2005).
   PubMed Web of Science ®Google Scholar
• Jones RN, Fritsche TR, Ge Y, Kaniga K, Sader HS. Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests. J. Antimicrob. Chemother.56, 1047–1052 (2005).
   PubMed Web of Science ®Google Scholar
• Kaniga K, Redman R, Pecoraro ML, Friedland M, Wikler M, Ge Y. Antibacterial activity of PPI-0903 against isolates in patients with complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), and hospital-acquired pneumonia (HAP). Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 16–19 December (2005) (Abstract F-1159).
   Google Scholar
• Ge Y, Thye DA, Talbot GH. In vitro activity of ceftaroline against isolates from patients with complicated skin and skin structure infections (cSSSI). Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract C2-864).
   Google Scholar
• Yanagihara K, Kurihara S, Seki M et al. Efficacy of SMP-601 against vancomycin-insensitive Staphylococcus aureus (VISA) in a model of hematogenous pulmonary infection. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract F1-237).
   Google Scholar
• Pace J, Stevens T, Hamrick J, Hoban D, Bouchillon S, Xerri L. PZ-601 susceptibility of Gram-positive pathogens causative for systemic and respiratory infections. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract F1-230).
   Google Scholar
• Stefani S, Mezzatesta M, Trovato G, Campanile F, Bongiorno D, Santagati M. Antibacterial activity of PZ-601 against well-characterized and recent clinical isolates of methicillin-resistant Staphylococcus aureus. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract F1-231).
   Google Scholar
• Pace JL, Stevens T, Hoban D et al. PZ-601 susceptibility of important Gram-negative bacterial species causative for community-acquired pneumonia (CAP), complicated skin and skin structure infections (cSSSI), and intra-abdominal infections (IAI). Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract F1-229).
   Google Scholar
• Young CL, Rusca A, Di Stefano AFD et al. Safety and multiple dose pharmacokinetics of intravenous PZ-601 (SMP-601): a novel carbapenem. Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract A-39).
   Google Scholar
• Bhavnani SM, Okusanya OO, Hammel JP et al. Population pharmacokinetic (PK) and Monte Carlo simulation (MCS) analyses to support Phase 2/3 PZ-601 (SMP-601) dosing strategies for complicated skin and skin structure infections (cSSSI). Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract A-40).
   Google Scholar
• Sahm DF, Draghi DC, Thornsberry C, Activity of ME1036, a novel anti-MRSA carbapenem, against Gram-positive and Gram-negative pathogens. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract F1-236).
   Google Scholar
• Kurazono M, Hirai Y, Takahata S et al. Efficacy of ME1036 against Enterobacteriaceae harboring a variety of β-lactamases including ESBLs. Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 30–2 November (2004) (Abstract F-331).
   Google Scholar
• Brown SD, Traczewski MM. ME1036: in vitro potency and spectrum of activity. Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract F1-342).
   Google Scholar
• Miossec C, Merdjan H, Hodgson J. Safety and toxicokinetics of NXL104, a broad spectrum β-lactamase inhibitor, in the rat. Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 16–19 December (2005) (Abstract F-1461).
   Google Scholar
• Levasseur P, Girard AM, Delachaume C et al. NXL104, a novel β-lactamase inhibitor, restores the bactericidal activity of ceftazidime against ESBL and AmpC producing strains of Enterobacteriaceae. Proceedings of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 27–30 September (2006) (Abstract F-127).
   Google Scholar
• Robbins MJ, Cassettari M, Dencer C et al. In vitro activity of NXL104 (NXL), a new β-lactamase inhibitor, in combination with cefpodoxime (CPD) and cefixime (CFM) against 3rd generation cephalosporin-resistant isolates of species of the Enterobacteriaceae. Proceedings of the 45th Interscience Conference onAntimicrobial Agents and Chemotherapy. Washington, DC, USA, 16–19 December (2005) (Abstract F-1161).
   Google Scholar
• Levasseur P, Girard AM, Miossec C, Lowther J, Rangaraju M, Hodgson J. Efficacy of NXL104 (previously AVE1330A), a novel broad spectrum β-lactamase inhibitor, in combination with ceftazidime (CAZ) in murine septicaemia and pneumonia. Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 16–19 December (2005) (Abstract F-1164).
   Google Scholar
• Merdjan H, Tarral A, Girard AM et al. Safety, single dose pharmacokinetics, and pharmacodynamics of β-lactamase inhibitor NXL104 in healthy young male adults. Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract A-809).
   Google Scholar
• Petersen PJ, Jones CH, Bradford PA. In vitro activity of piperacillin in combination with the penem β-lactamase inhibitor BLI-489 against a predictor panel of characterized -lactamase producing organisms. Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract F1-322).
   Google Scholar
• Petersen PJ, Jones CH, Bradford PA. In vivo efficacy of the penem β-lactamase inhibitor BLI-489 in combination with piperacillin in murine infection models. Proceedings of the47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract F1-323).
   Google Scholar
• Preželj A, Plantan I, Vilfan G et al. 10-ethylidene trinems as broad spectrum β-lactamase inhibitors. Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract F1-316).
   Google Scholar
• Kresken M, Brauers J, Preželj A. In vitro activity of LK-157, a novel tricyclic carbapenem β-lactamase inhibitor. Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September (2007) (Abstract F1-338).
   Google Scholar